Norway Point-Of-Care Molecular Diagnostics Market Size & Outlook

Name: Norway Point-Of-Care Molecular Diagnostics Market Size & Outlook
Creator: Grand View Research
License: https://www.grandviewresearch.com/horizon/info/terms-of-use

The point-of-care molecular diagnostics market in Norway is expected to reach a projected revenue of US$ 52.8 million by 2033. A compound annual growth rate of 5% is expected of Norway point-of-care molecular diagnostics market from 2025 to 2033.

Clinical Diagnostics
- Cancer Diagnostics
  - Point-of-Care Molecular Diagnostics Market Outlook

Norway point-of-care molecular diagnostics application outlook (Revenue, USD million, 2021-2033)
- Oncology
- Prenatal Testing
- Endocrinology
- Other Applications
- Hematology
  - Complete blood count (CBC)
  - Prothrombin time (PT)
  - Partial Thromboplastin Time (PTT)
  - Others
- Infectious Diseases
  - CT/NG
  - HIV POC
  - Clostridium difficile POC
  - HBV POC
  - Pneumonia or Streptococcus associated infections
  - Respiratory syncytial virus (RSV) POC
  - HPV POC
  - Influenza/Flu POC
  - HCV POC
  - MRSA POC
  - TB and drug-resistant TB POC
  - HSV POC
  - COVID-19
  - Other Infectious Diseases
Norway point-of-care molecular diagnostics technology outlook (Revenue, USD million, 2021-2033)
- PCR-based
- Genetic Sequencing based
- Hybridization based
- Microarray based
Norway point-of-care molecular diagnostics test location outlook (Revenue, USD million, 2021-2033)
- OTC
- POC
Norway point-of-care molecular diagnostics end-use outlook (Revenue, USD million, 2021-2033)
- Decentralised Labs
- Hospitals
- Home care
- Assisted Living Healthcare Facilities
- Others

Norway Point-Of-Care Molecular Diagnostics Market Size & Outlook

Data Tree

Sign up - it's easy, and free!